`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`
`
`IN RE: AFLIBERCEPT PATENT
`LITIGATION
`
`This Document Relates to All Cases
`
`
`
`MDL No. 1:24-MD-3103-TSK
`
`
`
`
`
`
`REGENERON PHARMACEUTICALS, INC.’S REPLY IN RESPONSE TO
`DEFENDANT SAMSUNG BIOEPIS CO., LTD.’S SUBMISSION REGARDING
`TEMPORARY RESTRAINING ORDERS
`
`To avoid any confusion regarding its position, Regeneron submits this reply in response to
`
`Samsung Bioepis’s submission regarding Regeneron’s potential motions for temporary restraining
`
`orders.1 Bioepis effectively asks the Court (at 1) to decide Regeneron’s pending motion for
`
`preliminary injunction. Regeneron is happy for the Court to do so without the need for TRO
`
`practice, if Bioepis agrees to remain off the market until the Court resolves the existing injunction
`
`motion or if the Court’s schedule allows a decision before May 18, 2024. That is the date on which
`
`FDA may approve biosimilar copies of Eylea® and, absent agreement or relief from the Court,
`
`enable Bioepis and the other Defendants to launch their products. Regeneron is available for oral
`
`argument on the injunction motions between now and then at the Court’s convenience.
`
`If the Court is not able to resolve the injunction motions by then, TROs would maintain
`
`the status quo for a limited time until the Court can do so. Regeneron will move for TROs on May
`
`14, 2024 or whenever and in whatever form the Court directs. However, Regeneron respectfully
`
`notes that TROs are limited to 14 days and only “good cause” or consent extensions, see Fed. R.
`
`Civ. P. 65(b)(2), because they are issued without hearing from the defendant, see ClearOne
`
`Advantage, LLC v. Kersen, 2024 WL 69918, at *2 (D. Md. Jan. 5, 2024) (quoting Hoechst Diafoil
`
`
`1 See Dkt. 39, No. 24-MD-3103; Dkt. 209, No. 23-CV-94; Dkt. 191, No. 23-CV-106.
`1
`
`
`
`
`
`
`
`
`Case 1:24-cv-00039-TSK Document 133 Filed 05/07/24 Page 2 of 4 PageID #: 284
`
`Co. v. Nan Ya Plastics Corp., 174 F.3d 411, 422 (4th Cir. 1999)).
`
`Alternately, if Defendants were to agree to remain off the market until the Court resolves
`
`the existing injunction motions, even if that resolution is after May 18, 2024, then Regeneron will
`
`
`
` CAREY DOUGLAS KESSLER & RUBY, PLLC
`
`/s/ Steven R. Ruby
`Steven R. Ruby (WVSB No. 10752)
`David R. Pogue (WVSB No. 10806)
`Raymond S. Franks II (WVSB No. 6523)
`707 Virginia Street East
`901 Chase Tower (25301)
`P.O. Box 913
`Charleston, West Virginia 25323
`(304) 345-1234
`sruby@cdkrlaw.com
`drpogue@cdkrlaw.com
`
`Attorneys for Plaintiff Regeneron
`Pharmaceuticals, Inc.
`
`
`forego filing TROs.
`
`
`
`Date: May 7, 2024
`
`Of Counsel:
`
`David I. Berl (admitted PHV)
`Ellen E. Oberwetter (admitted PHV)
`Thomas S. Fletcher (admitted PHV)
`Andrew V. Trask (admitted PHV)
`Teagan J. Gregory (admitted PHV)
`Shaun P. Mahaffy (admitted PHV)
`Kathryn S. Kayali (admitted PHV)
`Arthur J. Argall III (admitted PHV)
`Adam Pan (admitted PHV)
`Rebecca A. Carter (admitted PHV)
`Haylee N. Bernal Anderson (admitted PHV)
`Renee M. Griffin (admitted PHV)
`Jennalee Beazley* (admitted PHV)
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue, SW
`Washington, DC 20024
`(202) 434-5000
`dberl@wc.com
`eoberwetter@wc.com
`tfletcher@wc.com
`atrask@wc.com
`tgregory@wc.com
`smahaffy@wc.com
`kkayali@wc.com
`aargall@wc.com
`apan@wc.com
`rebeccacarter@wc.com
`handerson@wc.com
`rgriffin@wc.com
`jbeazley@wc.com
`
`
`
`
`2
`
`
`
`
`
`Case 1:24-cv-00039-TSK Document 133 Filed 05/07/24 Page 3 of 4 PageID #: 285
`
`
`*Admitted only in Pennsylvania; practice
`supervised by D.C. Bar members
`
`Elizabeth Stotland Weiswasser (admitted PHV)
`Anish R. Desai (admitted PHV)
`WEIL, GOTSHAL & MANGES
`767 Fifth Avenue
`New York, NY 10153
`Elizabeth.Weiswasser@weil.com
`Anish.Desai@weil.com
`
`Christopher M. Pepe (admitted PHV)
`WEIL, GOTSHAL & MANGES
`2001 M Street, NW
`Suite 600
`Washington, DC 20036
`Christopher.Pepe@weil.com
`
`Andrew E. Goldsmith (admitted PHV)
`Evan T. Leo (admitted PHV)
`Jacob E. Hartman (admitted PHV)
`Mary Charlotte Y. Carroll (admitted PHV)
`Sven E. Henningson (admitted PHV)
`Alyssa J. Picard (admitted PHV)
`KELLOGG, HANSEN, TODD, FIGEL &
` FREDERICK, P.L.L.C.
`1615 M Street, N.W., Suite 400
`Washington, D.C. 20036
`TEL: (202) 326-7900
`agoldsmith@kellogghansen.com
`eleo@kellogghansen.com
`jhartman@kellogghansen.com
`mcarroll@kellogghansen.com
`shenningson@kellogghansen.com
`apicard@kellogghansen.com
`
`Attorneys for Plaintiff Regeneron
`Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`Case 1:24-cv-00039-TSK Document 133 Filed 05/07/24 Page 4 of 4 PageID #: 286
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on May 7, 2024, I electronically transmitted the foregoing with the
`
`Court. Counsel of record for all parties will be served by electronic mail.
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Steven R. Ruby
`Steven R. Ruby (WVSB No. 10752)
`
`
`
`4
`
`
`
`